Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
CHRM2 Antibody (Center)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, E |
|---|---|
| Primary Accession | P08172 |
| Other Accession | P10980, P06199, Q9ERZ4, P41985, NP_000730.1, NP_001006628.1 |
| Reactivity | Human |
| Predicted | Bovine, Mouse, Pig, Rat |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 51715 Da |
| Antigen Region | 336-364 aa |
| Gene ID | 1129 |
|---|---|
| Other Names | Muscarinic acetylcholine receptor M2, CHRM2 |
| Target/Specificity | This CHRM2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 336-364 amino acids from the Central region of human CHRM2. |
| Dilution | WB~~1:1000 |
| Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | CHRM2 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | CHRM2 |
|---|---|
| Function | The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol. |
| Cellular Location | Cell membrane; Multi-pass membrane protein. Postsynaptic cell membrane; Multi-pass membrane protein. Note=Phosphorylation in response to agonist binding promotes receptor internalization {ECO:0000250|UniProtKB:P06199} |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The muscarinic cholinergic receptors belong to a larger family of G protein-coupled receptors. The functional diversity of these receptors is defined by the binding of acetylcholine to these receptors and includes cellular responses such as adenylate cyclase inhibition, phosphoinositide degeneration, and potassium channel mediation. Muscarinic receptors influence many effects of acetylcholine in the central and peripheral nervous system. The muscarinic cholinergic receptor 2 is involved in mediation of bradycardia and a decrease in cardiac contractility. Multiple alternatively spliced transcript variants have been described for this gene.
References
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
Ruano, G., et al. Pharmacogenomics 11(7):959-971(2010)
Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :
Cannon, D.M., et al. Mol. Psychiatry (2010) In press :
Bosker, F.J., et al. Mol. Psychiatry (2010) In press :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
